SUPN stock soars to 52-week high, hits $39.38 amid growth
Supernus Pharmaceuticals Inc (NASDAQ:SUPN) stock has reached a new 52-week high, touching $39.38 as the company continues to show robust performance in the pharmaceutical sector. According to ...
Supernus Pharmaceuticals exec sells $129,676 in stock
Padmanabh P. Bhatt, Senior Vice President of Intellectual Property and Chief Scientific Officer at Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN), recently executed a series of stock transactions ...
FiercePharma7d
Supernus' 4th try proves the charm with long-awaited FDA approval for Parkinson's infusion pump Onapgo
Three strikes and you’re out? Not for Supernus Pharmaceuticals and its Parkinson’s disease infusion pump. On its fourth attempt to pass muster with the FDA, the company’s SPN-830 ...
MedCity News7d
Supernus Wearable Device for Dosing Parkinson’s Drug Lands Long-Awaited FDA Approval
A new Supernus Pharmaceuticals medical device that continuously administers an old Parkinson’s disease drug is now FDA approved, giving patients another way to manage the motor control symptoms ...
CNN1y
Supernus Pharmaceuticals, Inc.
Supernus Pharmaceuticals, Inc. engages in the development and commercialization of products for the treatment of central nervous system diseases. It offers Trokendi XR, Oxtellar XR, APOKYN ...
Business Insider1mon
Jefferies Remains a Buy on Supernus Pharmaceuticals (SUPN)
In a report released yesterday, Andrew Tsai from Jefferies reiterated a Buy rating on Supernus Pharmaceuticals (SUPN – Research Report), with a price target of $40.00. The company’s shares ...